Committing to vaccine R&D: a global science policy priority
The amount of vaccine R&D performed, especially geared towards health issues affecting the developing world, is exceptionally undersized. Despite immunisation representing the most effective tool for achieving disease eradication, and the general consensus being optimistic about the development of a vaccine capable of fighting AIDS, Malaria and Tuberculosis, neither private nor public entities are investing sufficiently in the field. Reasons can be associated both with a lack of market incentives as well as with the low priority that these diseases set on Western political agendas. Though, seen through the Global Public Good lenses, it appears in the interest of high-income countries, their governments in primis, to invest public resources – financial and infra-structural – in vaccine R&D for global pandemics, as well as managing international cooperation through a global fund. The paper reviews a number of proposals put forward in the existing literature and offers a range of policy options. La cuantía invertida en I+D en vacunas, especialmente dirigida a cuestiones de salud que afectan al mundo en desarrollo, es excepcionalmente insuficiente. A pesar de que la inmunización representa el instrumento más efectivo para lograr la erradicación de enfermedades, y de que el consenso general es optimista sobre el desarrollo de una vacuna capaz de luchar contra el SIDA, la malaria y la tuberculosis, ni las entidades públicas ni las privadas están invirtiendo lo suficiente en este campo. Las razones de ello pueden asociarse tanto con una falta de incentivos de mercado como también con la baja prioridad que esas enfermedades tienen en las agendas políticas de Occidente. Si bien, visto desde la óptica de los Bienes Públicos Globales, parece que sería del interés de los países de rentas altas, e in primis de sus Gobiernos, el invertir recursos públicos – financieros y de infraestructura – en I+D en vacunas para las pandemias globales, así como gestionar la cooperación internac
(This abstract was borrowed from another version of this item.)
If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
References listed on IDEAS
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Cockburn, Iain M & Henderson, Rebecca M, 1998. "Absorptive Capacity, Coauthoring Behavior, and the Organization of Research in Drug Discovery," Journal of Industrial Economics, Wiley Blackwell, vol. 46(2), pages 157-182, June.
- Frank, Richard G., 2003. "New estimates of drug development costs," Journal of Health Economics, Elsevier, vol. 22(2), pages 325-330, March.
- DiMasi, Joseph A. & Hansen, Ronald W. & Grabowski, Henry G. & Lasagna, Louis, 1991. "Cost of innovation in the pharmaceutical industry," Journal of Health Economics, Elsevier, vol. 10(2), pages 107-142, July.
- Mazzoleni, Roberto & Nelson, Richard R., 1998. "The benefits and costs of strong patent protection: a contribution to the current debate," Research Policy, Elsevier, vol. 27(3), pages 273-284, July.
- Bengt-ake Lundvall & Bjorn Johnson, 1994. "The Learning Economy," Industry and Innovation, Taylor & Francis Journals, vol. 1(2), pages 23-42.
- Gambardella, Alfonso & Orsenigo, Luigi & Pammolli, Fabio, 2000. "Global Competitiveness in Pharmaceuticals: A European Perspective," MPRA Paper 15965, University Library of Munich, Germany.
- Archibugi, Daniele & Lundvall, Bengt-Ake (ed.), 2001. "The Globalizing Learning Economy," OUP Catalogue, Oxford University Press, number 9780199241095.
- Kenneth Arrow, 1962. "Economic Welfare and the Allocation of Resources for Invention," NBER Chapters, in: The Rate and Direction of Inventive Activity: Economic and Social Factors, pages 609-626 National Bureau of Economic Research, Inc.
- Grabowski, Henry G. & Vernon, John M., 1994. "Returns to R&D on new drug introductions in the 1980s," Journal of Health Economics, Elsevier, vol. 13(4), pages 383-406.
When requesting a correction, please mention this item's handle: RePEc:eee:respol:v:33:y:2004:i:10:p:1657-1671. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dana Niculescu)
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
If references are entirely missing, you can add them using this form.
If the full references list an item that is present in RePEc, but the system did not link to it, you can help with this form.
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your profile, as there may be some citations waiting for confirmation.
Please note that corrections may take a couple of weeks to filter through the various RePEc services.